Literature DB >> 14728821

Clinical manifestations and significance of post-traumatic thoracolumbar syringomyelia.

Yong Qiu1, Ze-zhang Zhu, Jin-yu Lü, Bin Wang, Wei-guo Li, Li-hua Zhu.   

Abstract

OBJECTIVE: To analyze the pathogenic mechanism and the clinical significance of post-traumatic thoracolumbar syringomyelia through reviewing the clinical manifestations.
METHODS: The data of 15 patients (14 males and 1 female, aged from 28 to 56 years, with an average of 36 years) with post-traumatic syringomyelia treated in our hospital from December 1997 to February 2002 were studied retrospectively. Two patients suffered from T11 fractures, 7 from T12 fractures and 6 from L1 fractures. There were 12 patients with burst fractures and 3 with fracture dislocations. Anterior decompression, bone graft, bone fusion and internal fixation were made on 6 patients, posterior decompression, bone graft, bone fusion and internal fixation on 1 patient, and non-surgical treatment on 8 patients.
RESULTS: Syringomyelia of the patients was diagnosed accurately with magnetic resonance imaging at 0.5-4 years after the original thoracolumbar fracture. The cavern was round in 6 cases, elliptic in 6 cases, and irregular in 3 cases. The patients also suffered from pain (80%), myodynamia attenuation in lower extremities (66.7%), aggravated spasm (46.7%), sensation loss or hypesthesia (46.7%), decreased coordinate function of lower extremities (20%) and autonomic nerve symptom (6.7%).
CONCLUSIONS: Post-traumatic thoracolumbar syringomyelia should be suspected if the patient has new neurological symptoms, such as myodynamia attenuation in lower extremities, after the neural function becomes stable for certain time.

Entities:  

Mesh:

Year:  2004        PMID: 14728821

Source DB:  PubMed          Journal:  Chin J Traumatol        ISSN: 1008-1275


  1 in total

1.  Double approach in thoraco-lumbar malunions.

Authors:  Jean-Paul Steib; Sami Mezghani; Yann Philippe Charles; Anca Mitulescu
Journal:  Eur Spine J       Date:  2009-10-01       Impact factor: 3.134

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.